Naturally occurring singleton residues in AAV capsid impact vector performance and illustrate structural constraints

被引:0
作者
L H Vandenberghe
E Breous
H-J Nam
G Gao
R Xiao
A Sandhu
J Johnston
Z Debyser
M Agbandje-McKenna
J M Wilson
机构
[1] Gene Therapy Program,Division of Transfusion Medicine, Department of Pathology and Laboratory Medicine
[2] University of Pennsylvania,Division of Molecular Medicine
[3] Laboratory for Molecular Virology and Gene Therapy,Department of Biochemistry and Molecular Biology
[4] Katholieke Universiteit Leuven,undefined
[5] Leuven,undefined
[6] Center for Structural Biology,undefined
[7] The McKnight Brain Institute,undefined
[8] College of Medicine,undefined
[9] University of Florida,undefined
来源
Gene Therapy | 2009年 / 16卷
关键词
gene transfer; AAV; vector; capsid; muscle; liver;
D O I
暂无
中图分类号
学科分类号
摘要
Vectors based on the adeno-associated virus (AAV) are attractive and versatile vehicles for in vivo gene transfer. The virus capsid is the primary interface with the cell that defines many pharmacological, immunological and molecular properties. Determinants of these interactions are often restricted to a limited number of capsid amino acids. In this study, a portfolio of novel AAV vectors was developed after a structure–function analysis of naturally occurring AAV capsid isolates. Singletons, which are particular residues on the AAV capsid that were variable in otherwise conserved amino acid positions, were found to impact on vector's ability to be manufactured or to transduce. Data for those residues that mapped to monomer–monomer interface regions on the particle structure suggested a role in particle assembly. The change of singleton residues to the conserved amino acid resulted in the rescue of many isolates that were defective on initial isolation. This led to the development of an AAV vector portfolio that encompasses six different clades and 3 other distinct AAV niches. Evaluation of the in vivo gene transfer efficiency of this portfolio after intravenous and intramuscular administration highlighted a clade-specific tropism. These studies further the design and selection of AAV capsids for gene therapy applications.
引用
收藏
页码:1416 / 1428
页数:12
相关论文
共 240 条
[1]  
Flotte TR(1995)Adeno-associated virus vectors for gene therapy Gene Therapy 2 357-362
[2]  
Carter BJ(2006)Adeno-associated virus serotypes: vector toolkit for human gene therapy Mol Ther 14 316-327
[3]  
Wu Z(2006)High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes J Virol 80 6192-6194
[4]  
Asokan A(2007)Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates Blood 109 1414-1421
[5]  
Samulski RJ(2005)Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy Blood 105 3079-3086
[6]  
Gao GP(2001)Rate limiting steps of AAV transduction and implications for human gene therapy Curr Gene Ther 1 137-147
[7]  
Lu Y(2004)Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors J Virol 78 3110-3122
[8]  
Sun X(2007)Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction Proc Natl Acad Sci USA 104 13104-13109
[9]  
Johnston J(2004)Clades of Adeno-associated viruses are widely disseminated in human tissues J Virol 78 6381-6388
[10]  
Calcedo R(2009)Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses J Infect Dis 199 381-390